Observational Study of Acalabrutinib in Patients with Chronic Lymphocytic Leukaemia in the United Kingdom - EPIC

Study identifier:D8220R00033

ClinicalTrials.gov identifier:NCT05557695

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A non-interventional, observational cohort study of Chronic Lymphocytic Leukaemia patients treated with acalabrutinib in the first-line setting through the UK Early Access Programme: Early access Programme outcomes In aCalabrutinib (EPIC).

Medical condition

Chronic Lymphocytic Leukemia, CLL

Phase

N/A

Healthy volunteers

No

Study drug

Acalabrutinib

Sex

All

Estimated Enrollment

350

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 17 Oct 2022
Estimated Primary Completion Date: 01 Apr 2026
Estimated Study Completion Date: 01 Apr 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

UKCLL Forum

Inclusion and exclusion criteria